View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 11, 2019updated 22 Nov 2021 8:58am

Beta Bionics receives breakthrough designation for blood sugar device

Beta Bionics has secured breakthrough device designation status from the US Food and Drug Administration (FDA) for its iLet Bionic Pancreas System.

Beta Bionics has secured breakthrough device designation status from the US Food and Drug Administration (FDA) for its iLet Bionic Pancreas System.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

iLet Bionic Pancreas is a wearable, autonomous system that leverages artificial intelligence (AI) and machine learning to deliver insulin and glucagon analogues for treating type 1 diabetes.

The device is intended for autonomous and continuous adaption to individual patient’s changing insulin needs.

Contrary to insulin pump therapy, iLet Bionic Pancreas System requires only the bodyweight of the user to initialise therapy.

As soon as users enter their body weight, the device automatically starts controlling blood glucose levels without needing the user to count carbohydrates, set insulin delivery rates, or deliver bolus insulin for meals or corrections.

Beta Bionics president and CEO Ed Damiano said: “We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes.

“We are particularly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.”

The device has been granted breakthrough designation in insulin-only, glucagon-only and bihormonal configurations.

It has also been approved for use alongside Zealand Pharma’s dasiglucagon, a glucagon analogue with a unique stability profile in a ready-to-use aqueous solution.

Beta Bionics partnered with Zealand Pharma on co-development activities.

In June, Beta Bionics announced favourable outcomes from a home-use study of its iLet Bionic Pancreas System using pre-filled cartridges of Zealand Pharma’s dasiglucagon.

In May, the randomised, two-period, cross-over, home-use trial evaluated iLet’s operational performance when used with bihormonal configuration compared to insulin-only configuration.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network